Table 1.
Baseline Characteristics
| Control (n = 127) | NO (n = 117) | |
|---|---|---|
| Age, yr | 48.4 ± 8.6 | 48.7 ± 9.5 |
| Sex | ||
| Female | 75 (59) | 65 (56) |
| Male | 52 (41) | 52 (44) |
| BMI, kg/m2 | 22.1 ± 2.8 | 21.8 ± 2.8 |
| BSA, m2 | 1.63 (1.52–1.71) | 1.63 (1.51–1.74) |
| Admission | ||
| Rheumatic disease | 119 (94) | 107 (91) |
| Congenital valve disease | 2 (1) | 2 (2) |
| Infectious valve disease | 6 (5) | 8 (7) |
| Surgery | ||
| AVR | 1 (1) | 0 (0) |
| MVR+AVR | 45 (35) | 49 (42) |
| MVR+AVR+TVP/R | 79 (62) | 68 (58) |
| MVR+TVP/R | 2 (2) | 0 (0) |
| NYHA | ||
| II | 53 (42) | 45 (39) |
| III | 73 (57) | 69 (59) |
| IV | 0 (0) | 1 (1) |
| Undisclosed | 1 (1) | 2 (2) |
| PAH | 61 (48) | 63 (54) |
| EuroSCORE II, % | 1.1 (0.9–1.6) | 1.2 (0.9–1.6) |
| Serum creatinine, mg/dl | 1.06 (0.97–1.17) | 1.04 (0.96–1.14) |
| eGFR, ml/min/1.73 m2 | 70.3 ± 12.4 | 71.1 ± 15.0 |
| eGFR < 60 ml/min/1.73 m2 | 22 (17) | 24 (21) |
Definition of abbreviations: AVR = aortic valve replacement; BMI = body mass index; BSA = body surface area; eGFR = estimated glomerular filtration rate; EuroSCORE II = European system for cardiac operative risk evaluation; MVR = mitral valve replacement; NO = nitric oxide; NYHA = New York Heart Association; PAH = pulmonary artery hypertension, defined as systolic pulmonary arterial pressure > 38 mm Hg at rest on transthoracic echocardiography before surgery; TVP/R = tricuspid valve plasty or replacement.
Data represent n (%), mean ± SD, or median (IQR). P > 0.05 for all comparisons.